A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck

PURPOSE: To determine the disease control rate and toxicity of treating patients with aggressive cutaneous squamous cell carcinoma (CSCC) with neoadjuvant gefitinib. EXPERIMENTAL DESIGN: A prospective phase II clinical trial evaluating neoadjuvant gefitinib given prior to standard treatment with sur...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Lewis, Carol M, Glisson, Bonnie S, Feng, Lei, Wan, Fiona, Tang, Ximing, Wistuba, Ignacio I, El-Naggar, Adel K, Rosenthal, David I, Chambers, Mark S, Lustig, Robert A, Weber, Randal S
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167936/
https://ncbi.nlm.nih.gov/pubmed/22261807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1951
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires